189 related articles for article (PubMed ID: 36306047)
1. Synthesis, characterization and evaluation of prenylated chalcones ethers as promising antileishmanial compounds.
Hernández-Rivera JL; Espinoza-Hicks JC; Chacón-Vargas KF; Carrillo-Campos J; Sánchez-Torres LE; Camacho-Dávila AA
Mol Divers; 2023 Oct; 27(5):2073-2092. PubMed ID: 36306047
[TBL] [Abstract][Full Text] [Related]
2. Novel prenyloxy chalcones as potential leishmanicidal and trypanocidal agents: Design, synthesis and evaluation.
Espinoza-Hicks JC; Chacón-Vargas KF; Hernández-Rivera JL; Nogueda-Torres B; Tamariz J; Sánchez-Torres LE; Camacho-Dávila A
Eur J Med Chem; 2019 Apr; 167():402-413. PubMed ID: 30784876
[TBL] [Abstract][Full Text] [Related]
3. The chemotherapeutic potential of chalcones against leishmaniases: a review.
Tajuddeen N; Isah MB; Suleiman MA; van Heerden FR; Ibrahim MA
Int J Antimicrob Agents; 2018 Mar; 51(3):311-318. PubMed ID: 28668673
[TBL] [Abstract][Full Text] [Related]
4. Computer-aided discovery of two novel chalcone-like compounds active and selective against Leishmania infantum.
Gomes MN; Alcântara LM; Neves BJ; Melo-Filho CC; Freitas-Junior LH; Moraes CB; Ma R; Franzblau SG; Muratov E; Andrade CH
Bioorg Med Chem Lett; 2017 Jun; 27(11):2459-2464. PubMed ID: 28434763
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of leishmaniasis part-VIII: synthesis and bioevaluation of novel chalcones.
Suryawanshi SN; Chandra N; Kumar P; Porwal J; Gupta S
Eur J Med Chem; 2008 Nov; 43(11):2473-8. PubMed ID: 18243420
[TBL] [Abstract][Full Text] [Related]
6. The role of natural anti-parasitic guided development of synthetic drugs for leishmaniasis.
Pal R; Teli G; Akhtar MJ; Matada GSP
Eur J Med Chem; 2023 Oct; 258():115609. PubMed ID: 37421889
[TBL] [Abstract][Full Text] [Related]
7. The 2',4'-dihydroxychalcone could be explored to develop new inhibitors against the glycerol-3-phosphate dehydrogenase from Leishmania species.
Passalacqua TG; Torres FA; Nogueira CT; de Almeida L; Del Cistia ML; dos Santos MB; Dutra LA; Bolzani VS; Regasini LO; Graminha MA; Marchetto R; Zottis A
Bioorg Med Chem Lett; 2015 Sep; 25(17):3564-8. PubMed ID: 26169126
[TBL] [Abstract][Full Text] [Related]
8. Molecular Targets for Chalcones in Antileishmanial Drug Discovery.
de Santiago-Silva KM; da Silva Gomes GF; Perez CC; da Silva Lima CH; de Lima Ferreira Bispo M
Mini Rev Med Chem; 2023; 23(14):1414-1434. PubMed ID: 36705240
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of hybrid sulfonamide-chalcones with potential antileishmanial activity.
de Oliveira NS; de Souza LG; de Almeida VM; Barreto ARR; Carvalho-Gondim F; Schaeffer E; Santos-Filho OA; Rossi-Bergmann B; da Silva AJM
Arch Pharm (Weinheim); 2024 Mar; 357(3):e2300440. PubMed ID: 38048546
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy of leishmaniasis part X: synthesis and bioevaluation of novel terpenyl heterocycles.
Tiwari A; Kumar S; Suryawanshi SN; Mittal M; Vishwakarma P; Gupta S
Bioorg Med Chem Lett; 2013 Jan; 23(1):248-51. PubMed ID: 23177254
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones.
Chen M; Zhai L; Christensen SB; Theander TG; Kharazmi A
Antimicrob Agents Chemother; 2001 Jul; 45(7):2023-9. PubMed ID: 11408218
[TBL] [Abstract][Full Text] [Related]
12. Insights about resveratrol analogs against trypanothione reductase of
da Silva AD; Dos Santos JA; Machado PA; Alves LA; Laque LC; de Souza VC; Coimbra ES; Capriles PVSZ
J Biomol Struct Dyn; 2019 Jul; 37(11):2960-2969. PubMed ID: 30058445
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel halogen rich salicylanilides as potential antileishmanial agents.
Lal J; Ramalingam K; Meena R; Ansari SB; Saxena D; Chopra S; Goyal N; Reddy DN
Eur J Med Chem; 2023 Jan; 246():114996. PubMed ID: 36565533
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
[TBL] [Abstract][Full Text] [Related]
15. Identification of dehydroxy isoquine and isotebuquine as promising antileishmanial agents.
Romero AH; Rodríguez N; López SE; Oviedo H
Arch Pharm (Weinheim); 2019 May; 352(5):e1800281. PubMed ID: 30994941
[TBL] [Abstract][Full Text] [Related]
16. Antileishmanial Activities of Medicinal Herbs and Phytochemicals In Vitro and In Vivo: An Update for the Years 2015 to 2021.
Hassan AA; Khalid HE; Abdalla AH; Mukhtar MM; Osman WJ; Efferth T
Molecules; 2022 Nov; 27(21):. PubMed ID: 36364404
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, in vitro - In vivo biological evaluation of novel thiazolopyrimidine compounds as antileishmanial agent with PTR1 inhibition.
Istanbullu H; Bayraktar G; Karakaya G; Akbaba H; Perk NE; Cavus I; Podlipnik C; Yereli K; Ozbilgin A; Debelec Butuner B; Alptuzun V
Eur J Med Chem; 2023 Feb; 247():115049. PubMed ID: 36577215
[TBL] [Abstract][Full Text] [Related]
18. Identification of chalcone-based antileishmanial agents targeting trypanothione reductase.
Ortalli M; Ilari A; Colotti G; De Ionna I; Battista T; Bisi A; Gobbi S; Rampa A; Di Martino RMC; Gentilomi GA; Varani S; Belluti F
Eur J Med Chem; 2018 May; 152():527-541. PubMed ID: 29758517
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, Antileishmanial Activity and
de Aquino TM; França PHB; Rodrigues ÉEES; Nascimento IJS; Santos-Júnior PFS; Aquino PGV; Santos MS; Queiroz AC; Araújo MV; Alexandre-Moreira MS; Rodrigues RRL; Rodrigues KAF; Freitas JD; Bricard J; Meneghetti MR; Bourguignon JJ; Schmitt M; da Silva-Júnior EF; de Araújo-Júnior JX
Med Chem; 2022; 18(2):151-169. PubMed ID: 33593264
[TBL] [Abstract][Full Text] [Related]
20. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action.
Zhai L; Chen M; Blom J; Theander TG; Christensen SB; Kharazmi A
J Antimicrob Chemother; 1999 Jun; 43(6):793-803. PubMed ID: 10404318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
